Background and Aims: Cannabinoid receptor stimulation may have positive symptomatic effects on inflammatory bowel disease [IBD] ∆ARE/+ mice. Furthermore, GP-1a enhanced Treg suppressive function with a concomitant increase in IL-10 secretion. GP-1a attenuated murine ileitis, as demonstrated by improved histological scoring and decreased inflammatory cytokine expression. Lastly, CB 2 R is downregulated in both chronically inflamed TNF ∆ARE/+ mice and in IBD patients. Conclusions: In summary, the endocannabinoid system is induced in murine ileitis but is downregulated in chronic murine and human intestinal inflammation, and CB 2 R activation attenuates murine ileitis, establishing an anti-inflammatory role of the endocannabinoid system.
Introduction
Inflammatory bowel disease [IBD] , including Crohn's Disease [CD] and ulcerative colitis, is one of the most costly, prevalent gastrointestinal disorders and affects approximately 1.6 million people in the USA. 1 Chronic inflammation of the gastrointestinal tract in IBD places a significant burden on affected individuals, not only due to poor quality of life and the long-term risk of malignancy, but also due to recurrent symptoms of abdominal pain, bloody diarrhoea, and weight loss, as well as the growth failure, impaired bone mineralisation and pubertal delay commonly seen in paediatric-onset IBD. 2 The complex factors underlying IBD pathogenesis are still incompletely understood, but it is generally recognised that IBD emerges due to an aberrant immune response. CD4 + T cells act as key mediators of intestinal inflammation and therefore represent an ideal target for therapeutic treatment of IBD. Of particular significance are CD4 + FoxP3 + regulatory T cells [Tregs] , which play a crucial role in maintaining gut homeostasis by suppressing inappropriate immune responses. Expression of the transcription factor FoxP3 is vital for the regulatory activity of Tregs, and thus mutated FoxP3 in both humans and mice results in severe autoimmunity, including immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome [IPEX] in humans. 3 Novel modulatory approaches which promote the regulatory pathway in T cells, whereby excessive effector cell responses are curtailed, hold considerable potential as future therapeutic approaches for the treatment of IBD.
The limited benefits, rapid loss of efficacy, and multiple longterm risks, including malignancy, infection, and low bone density, 4 of current immunosuppressive therapies have influenced affected individuals and physicians alike to urge the development of alternate therapeutic strategies for the treatment of IBD. The endogenous cannabinoid [endocannabinoid] system is one pathway that is rapidly gaining attention as a novel therapeutic target for its immunosuppressive effects 5 and, specifically in IBD, for its possible analgesic and anti-inflammatory effects. 6 As of March 2017, 28 states and Washington DC have legalised cannabis for medical purposes, and limited observational studies have demonstrated that medical marijuana, through interaction with the endogenous cannabinoid system [ECS] , can potentially be used to alleviate a number of IBDassociated intestinal symptoms including reducing nausea, stool frequency, and abdominal pain, while improving appetite and weight gain. 7 However, it is unclear if the symptomatic relief experienced by patients using cannabis in IBD is accompanied by improvement of intestinal inflammation or any real disease-modifying effect. 8 Indeed, one such study showed that the patients with Crohn's disease who used cannabis had worse disease prognosis and higher tendency toward surgical intervention. 9 It is this uncertainty of the risks, benefits, and true impact of cannabis on IBD that has driven the intensification of basic science research investigating the biological effects of manipulation of the ECS in intestinal inflammation.
The ECS consists of endogenous ligands termed endocannabinoids, including anandamide [AEA] and 2-arachidonoylglycerol [2-AG], which mainly act via two classic cannabinoid heterotrimeric G-protein-coupled receptors: cannabinoid receptor 1 [CB 1 R] and cannabinoid receptor 2 [CB 2 R]. They also act through non-classical receptors: transient receptor potential vanilloid type 1 [TRPV1] and the orphan G-protein-coupled receptor GPR55. 2, 10 The CB 1 R modulates neurotransmitter release and is found on central and peripheral neurons, including within the enteric nervous system. 10 The CB 2 R has been shown to be mostly expressed on neutrophils, macrophages, subsets of T and B cells, and epithelial cells, 11 and thus is mainly associated with immune function. 12 The ECS also includes the proteins involved in endocannabinoid biosynthesis and degradation; fatty-acid amide hydrolase [FAAH] degrades AEA to arachidonic acid and ethanolamine, 13 and monoacylglycerol lipase [MAGL] degrades 2-AG to arachidonic acid and glycerol. 14 The ECS regulates gastrointestinal function through its effects on gastric secretions, gut-brain signalling, gut motility, and the gut microbiome, and significantly influences murine intestinal inflammation. 15 A recent review on cannabinoids in murine colitis models demonstrated that manipulation of the endocannabinoid system had immunomodulatory effects dependent on complex interactions of specific receptor pathways.
2 CB 1 R activation [16] [17] [18] [19] [20] [21] and CB 2 R activation 19, 20, [22] [23] [24] [25] [26] both ameliorated acute colitis. Furthermore, inflamed colonic epithelium and lamina propria [LP] immune cells have increased expression of the CB 2 R, 27 and activation of epithelial CB 2 R inhibits tumour necrosis factor alpha [TNF-α]-induced CXCL8 release in vitro. 28 Our studies made use of the TNF ∆ARE/+ mouse model of Crohn'slike ileitis. 29 These mice are generated by the deletion of 69 bp within the AU-rich element of the TNF gene, causing systemic overproduction of TNF and consequently chronic ileal inflammation representative of human CD. The compelling similarities with human CD in the pathogenesis and histological presentation of disease in this model reinforce its value and relevance in our investigation of the role of cannabinoids in mediating T cell homeostasis.
In summary, development of novel therapeutic pathways is imperative in the treatment of IBD. Limited data are supportive of symptomatic improvement with cannabis use in IBD, but the role of cannabinoids in immune response and immunostimulation is incompletely understood. Because CB 2 R is expressed by CD4 + T cells 30 and is upregulated in inflamed LP immune cells, and based on the amalgamation of the murine colitis studies described, a central anti-inflammatory role of the CB 2 R is suggested. We hypothesised that stimulation of CB 2 R would positively affect disease outcomes in murine ileitis. In our study, we investigated inflammation-induced changes in cannabinoid tone in both murine and human intestinal tissue, and assessed the role of cannabinoids as endogenous modulators of intestinal inflammation by defining the effect of pharmacological CB 2 R targeting on inflammation, T cell function, and phenotype. /J] were obtained from Jackson Laboratories. Mice were kept under specific pathogen-free conditions, and faecal samples were routinely negative for Helicobacter species, protozoa, and helminthes. Animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Colorado Denver. 
Materials and Methods

Mice
Analysis of endogenous cannabinoid tone
In vitro suppression assays
Treg suppression assays were performed as previously described. [MLN] , and ilea were excised for flow cytometric analysis, histological assessment of ileitis, and cytokine analyses. Ileal sections were fixed in 10% formalin, and stained with haematoxylin and eosin. Histological assessment of ileitis was performed using a standardised semi-quantitative scoring system, as described previously. 34 Representative micrographs were obtained using an Olympus IX83 inverted microscope with cellSens Dimension v1. 16 
Quantification of cytokine production
Evaluation of cannabinoid receptor expression in Crohn's disease patients
The study protocol was approved by the Ethical Committee of the University Hospital, Tuebingen, Germany. All patients and controls gave their written, informed consent to participation. Biopsies from the terminal ileum and colon were sampled during routine colonoscopy at the Robert Bosch Hospital, Stuttgart, Germany, and were immediately stored in liquid nitrogen for subsequent processing and analysis. Diagnosis was performed according to standard criteria using clinical, radiological, endoscopic, and histopathological methods. Patients with CD were grouped according to standard Vienna classifications, designating L1 as CD with exclusive ileal involvement, L2 as CD with solely colonic involvement, and L3 as CD with ileocolonic involvement.
RNA preparation from human tissue and quantification of mRNA expression
RNA from human tissue was isolated using TRIzol Reagent [Life Technologies] according to manufacturer's protocol. cDNA synthesis was performed using a reverse transcription kit [Promega] and oligo[dT]15-primer. An amount of cDNA corresponding to 10 ng of RNA was applied in all assays. For quantification, we used SYBR Green I [Roche] and the Roche LightCycler 480 system. Absolute copy numbers were calculated from the crossing point [Cp] values according to respective standard plasmid curves, generated for all targets. Plasmid standards were designed using a TOPO TA Cloning Kit [Invitrogen] and confirmed by sequencing. Results were normalised to β-actin [see Table 1 for primers].
Statistics
Statistical analyses were performed using one-or two-tailed Student's t test [as appropriate], Mann-Whitney U-test [for non-normally distributed groups], and Spearman rank analysis to test for correlation. In the absence of evidence regarding expression of CB receptors in the inflamed ileum, we chose to employ a more conservative twotailed t test. In contrast, interventional studies were assessed using a one-tailed t test consistent with our directional research hypothesis to be tested. Graphs are presented as mean ± standard error of the mean [SEM], generated using GraphPad Prism software. Values of p < 0.05 were considered statistically significant.
Results
Murine ileitis induces the endocannabinoid system
The ECS is induced in acute colitis models using dextran sulphate sodium [DSS] Due to the expression profile of the CB 2 R in the ileum, and because CB 2 R is preferentially expressed on lymphocytes and other immune cells, we identified the CB 2 R as our receptor of interest. We found that in line with the results of real-time [RT]-PCR, CB 2 R protein was prominently increased in the actively inflamed ilea of TNF ∆ARE/+ mice compared with WT littermates [ Figure 1C ]. In summary, the compilation of data in Figure 1 highlights the induction of the ECS at the receptor level, and to a much lesser extent at the ligand level, in the setting of active murine ileitis. Furthermore, CB 2 R mRNA expression is more significantly elevated than CB 1 R expression in the ilea of actively inflamed TNF ∆ARE/+ mice and is preferentially expressed on immune cells, distinguishing CB 2 R as the key receptor of interest in our investigation.
CB 2 R is preferentially upregulated on regulatory T cells in murine ileitis, and targeting with GP-1a enhances suppressive function
In view of the fact that cannabinoid receptors are expressed by CD4 + T cells, key regulators of intestinal inflammation, and based on their upregulation in acute murine ileitis, we focused our investigational efforts on elucidation of the role of the cannabinoid receptors on CD4 + T cell phenotype and function during inflammation. First, we compared cannabinoid receptor expression on CD4 + Tregs with that on CD4 + non-Tregs isolated from actively inflamed 8-12-week-old male TNF ∆ARE/+ mice and age-matched male WT controls [n = 3 per group]. Tregs were magnetically enriched from splenocytes based on expression of CD25, and although CD25 can be induced on activated non-Treg cells especially in vitro, our experience with TNF ΔARE/+ mice indicates that CD25 is not expressed on non-Tregs, even in the inflamed lamina propria. 
Gene
Sense Antisense Figure 2C ].
In summary, Figure 2A identified a preferential expression of CB 1 R and CB 2 R on Tregs, and this effect was even more pronounced for CB 2 R expression in the setting of active murine ileitis, implying involvement of the CB 2 R on Tregs in the active inflammatory pathway. Figure 2B indicates the ability of CB 2 R stimulation with GP-1a to enhance Treg suppression, with a concomitant increase in IL-10 production suggesting an anti-inflammatory role for CB 2 R stimulation in CD4 + T cells. Figure 2C indicates a direct effect of GP-1a on the expression of CB 1 R and CB 2 R on TNF ∆ARE/+ Teff cells.
CB 2 R stimulation attenuates murine ileitis
To investigate the potential anti-inflammatory role of CB 2 R stimulation in active murine ileitis, we performed a treatment study using selective CB 2 R ligand GP-1a. Eight-week-old male TNF ∆ARE/+ mice received pulsatile 2-week treatment with either GP-1a or vehicle [n = 9 mice per treatment group], and ilea were then isolated at 10 weeks of age for blinded histology review by a pathologist using the previously described Burns method. 34 We found that CB 2 R stimulation with GP-1a led to histological improvement of ileitis of TNF ∆ARE/+ mice [ Figure 3 ]. Notably, both active inflammation characterised by granulocytic infiltration, and chronic inflammation characterised by lymphocytic infiltration, significantly improved [p < 0.05] in response to CB 2 R ligand treatment [ Figure 3 ]. There was a trend of decreased villus architecture distortion in mice treated with GP-1a, although this improvement did not reach statistical significance [p = 0.07]. These data support the findings in Figure 2 , suggesting an anti-inflammatory role of CB 2 R stimulation in murine ileitis.
CB 2 R receptor stimulation reduces inflammatory infiltrate
To further elucidate the anti-inflammatory effect of CB 2 R stimulation in murine ileitis, we assessed cells from spleen, MLN, and ileal LP from 10-week-old TNF ∆ARE/+ mice following GP-1a treatment by flow cytometry. We found a significant decrease [2.2 ± 0.3% to 1.4 ± 0.2; p < 0.05] in IFNγ-producing Th1 cells in the TNF ∆ARE/+ LP when treated with GP-1a as compared with vehicle control, as well as a decrease, albeit non-significant, in the expression of IFNγ in both spleen and MLN [p = 0.1 and 0.3, respectively] [ Figure 4A , B]. Furthermore, we found that whereas the frequency of CD4 +
FoxP3
+ Tregs was unchanged in the LP of GP-1a treated mice, the proportion of Tregs producing IL-10 was significantly increased [3.9 ± 1% to 7.1 ± 0.9 %; p < 0.05]. Consistent with this finding, an ELISA revealed a significant increase in IL-10 in the supernatants of ileal explant culture of GP-1a treated mice [252.8 ± 43.7 pg/mg; p < 0.05] as compared with vehicle control [123.1 ± 26.3 pg/mg; p < 0.05] [ Figure 4C ].
Collectively, the data presented in Figures 3 and 4 indicate that CB 2 R stimulation ameliorates inflammation and reduces inflammatory infiltrate in murine ileitis. We also assessed mucosal CXCL8 expression to confirm the inflammatory status of the included samples. In the ileum, controls displayed a mean level of 546.3 copies/10 ng total RNA [417.4 SEM], non-inflamed ileal CD patients showed 380.2 ± 120.8, and inflamed samples 7873 ± 3036 copies of CXCL8/10ng total RNA.
In the colon, controls displayed an average of 115.1 CXCL8 copies/10 ng total RNA, non-inflamed colonic CD patients showed on average 339.9 ± 138, and inflamed samples 4599 ± 2097 copies of CXCL8/10 ng total RNA. Patient characteristics are listed in Table 2 . The age distribution of the studied patients was typical for this disease, as was the balanced gender ratio. For our ileal studies, we compared ilea of CD patients, who all belonged to Vienna classification L1 or L3 [n = 58], with those of healthy controls [n = 24], and for colonic tissue, we combined L2 and L3 subgroups as colonic CD [n = 49], which we again compared with healthy controls [n = 25] . Gene expression on the mRNA level for both CNR1 and CNR2 was relatively low in all studied groups. However, expression was consistently detected in all analysed samples. Interestingly, we found Figure 5C ] in the ilea of non-inflamed CD patients. In active disease, the reduction was less pronounced but still present. In the colon, however, both receptors were markedly higher in noninflamed colonic CD patients [p < 0.01 for CNR1 and p < 0.05 for CNR2] [ Figure 5B , D]. Since the pattern of expression of the two receptors showed notable similarity, we checked for correlation. In both tissues, we found a moderate but statistically highly significant degree of correlation [p < 0.001] [ Figure 5E , F].
In summary, Figure 5 reveals an overall marked reduction in cannabinoid receptor expression in the ilea of CD patients with chronic inflammation compared with healthy controls, though expression of both CB 1 R and CB 2 R was increased in active disease compared with non-inflamed patients nonetheless. In the colon, we saw an increase in cannabinoid receptor expression with disease, to a significant extent in non-inflamed CD patients.
Discussion
Our experiments demonstrate that the ECS is induced by active intestinal inflammation at receptor mRNA and protein expression levels, and to a much lesser extent at the ligand level. Similar results of receptor expression have been reported in chemical models of intestinal inflammation. 17, 19, 21, [37] [38] [39] These findings are also supported from a broader perspective, where CB 2 R expression is reported to increase in early inflammatory events in both the central nervous system [CNS] and peripheral tissue. 40, 41 Thus, the effects of the ECS in models of gut inflammation appear to be primarily due to increased receptor expression and not ligand expression. In addition, these effects may be specific to the TNF ∆ARE/+ model of CD, as there was no induction of CB 1 R and CB 2 R seen in an acute infectious Salmonella colitis model. The compilation of past evidence and our current results validate the ECS as a promising therapeutic target in inflammatory conditions such as IBD.
Intriguingly, we found that both cannabinoid receptors were preferentially upregulated on Tregs when compared with CD4 + CD25
Neg
Teff cells. In light of the importance of Treg in maintaining normal gut homeostasis, we proceeded to examine the role of ECS activity in governing Treg function. We observed that treatment in vitro with CB 2 R ligand GP-1a led to improved suppression of Teff proliferation in the setting of inflammation. Increased IL-10 in the supernatants of treated co-cultures suggests that the effect of GP-1a is a result of improved Treg suppressive function, although increased susceptibility of Teff to suppression is also a possibility. Our efforts in investigating the mechanism of decreased Teff proliferation with Gp-1a revealed that Gp-1a appears to have some direct effect on Teff; however, this effect was lost in the absence of Tregs, suggesting a possible effect on Teff resistance to suppression. In addition, GP-1a does not directly induce apoptosis [ Supplementary Figure 3 , available as Supplementary data at ECCO-JCC online]. We then demonstrated that CB 2 R stimulation with GP-1a in vivo significantly attenuated active murine ileitis, as determined histologically and by assessment of inflammatory infiltrate. We found that histological features of ileitis, such as leukocyte infiltration, goblet cell hyperplasia, and muscularis hypertrophy, were markedly decreased with GP-1a treatment. Furthermore, we found a decrease in the frequency of infiltrating IFNγ-producing Th1 cells and an increase in the proportion of IL-10-producing Tregs, consistent with an overall increased secretion of IL-10 from the ileal tissue of GP-1a-treated mice. These in vivo results are supported by previous studies which showed GP-1a-induced inhibition of Th1 and Th17 differentiation in vitro, under both polarising and non-polarising conditions. 33 Overall, manipulation of the CB 2 R has both pro-regulatory and anti-inflammatory effects, as evidenced by enhanced suppression of Teff, increased IL-10 production, and decreased Th1 cell infiltration. Interestingly, the previously accepted classification of GP-1a as a selective CB 2 R agonist 42, 43 has more recently been debated. Soethoudt et al. profiled various CB 2 R ligands and confirmed that GP-1a is one of the most selective compounds for the CB 2 R and is an active AEA reuptake inhibitor but, in contrast to previous reports, it acts in vitro as an inverse agonist at the CB 2 R while it is inactive at the CB 1 R. 44 However, cannabinoid signalling is complex, and evidence shows that cannabinoid receptor ligands may have varying pharmacological roles in native versus recombinant systems. 45 Marini et al. characterised several cannabinoid receptor ligands in tissue that natively express CB 2 R, and found that certain cannabinoid receptor ligands can act as an agonist in human spleen but act in vitro as an inverse agonist in cells over-expressing the human CB 2 R. 45 Although GP-1a was not specifically investigated, this work demonstrated that some cannabinoid ligands that are classified as CB 2 R inverse agonists can have anti-nociceptive actions in vivo, and therefore demonstrate CB 2 R agonist properties. 45 As a G-protein-coupled receptor, CB 2 Rspecific properties such as tethering of G-protein subunits, G-protein signalling regulators, receptor phosphorylation, and compartmentalisation of signalling elements within the membrane influence the efficacy of CB 2 R ligands, 46 and these factors may explain the differences in the pharmacological profile of ligands between species and between the native and recombinant cell systems. 45 Our experiments did not define the exact mechanism of GP-1a-attenuated inflammation, but we hypothesise that there is a critical importance in selecting a CB 2 R inverse agonist in the therapeutic targeting of inflammation, as well as in the function of G-protein-coupled receptors such as the CB 2 R. It is well established that G-protein-coupled receptors such as the CB 2 R are constitutively active, and will recruit known elements of cellular desensitisation leading to constitutive desensitisation. 47 Likewise, G-protein-coupled receptors are phosphorylated by G-protein-coupled receptor kinase and lead to desensitisation at a similar extent and rate in both the absence and presence of an agonist. 47 A study by Bouaboula et al. demonstrated that inverse agonism with SR144528 blocked the constitutive activation of CB 2 R and did not allow desensitisation of the receptor to occur. 48 Therefore, G-protein-coupled receptors such as the CB 2 R require treatment with an inverse agonist in order to reverse desensitisation, and thus allow activation of the receptor and its downstream pathways. We hypothesise that, in a similar mechanism, GP-1a acts upon the CB 2 R with inverse agonism in order to reverse desensitisation and restore the innate anti-inflammatory signalling system of the ECS. One critical aspect of this assumption is that our experiments were performed using fetal bovine sera containing endocannabinoids, 49 and in contrast, our preliminary in vitro experiments using serum-free media have demonstrated that the effect of GP-1a treatment is abrogated in the absence of these endogenous cannabinoids [data not shown]. This incidental but significant observation reinforces our hypothesis that resensitisation of the CB 2 R allows restoration of endogenous cannabinoid signalling and thereby resolution of inflammation.
Whereas we propose that GP-1a acts upon the CB 2 R with inverse agonism in order to allow receptor resensitisation, promoting the endocannabinoid system to act at the CB 2 R to ameliorate murine ileitis, our data reveal a novel and overarching role of Tregs in this process. It is well established that CD4 + T cells are key mediators of intestinal inflammation, and more specifically CD4 +
FoxP3
+ cells [Tregs] suppress inappropriate immune responses and maintain gut homeostasis. Our experiments parallel this concept, and we have demonstrated that CB 1 R and CB 2 R are upregulated on Tregs in the setting of active murine ileitis. More importantly, usng a Treg suppression assay to assess the suppressive function of Tregs, we found that treatment in vitro with CB 2 R ligand GP-1a led to improved suppressive function of Tregs in the setting of inflammation. When we investigated the suppressive capacity of Tregs lacking the CB 2 R, our data showed no significant difference in their suppressive function. It should be noted, however, that this assay was conducted in the absence of inflammation-induced upregulation of the CB 2 R. This experimental finding is therefore unsurprising, as CB 2 R shows low expression overall in the absence of inflammation, and thus the CB 2 R would not be expected to play a role in Treg suppressive function in a WT system. Efforts to cross CB 2 R-deficient mice with the TNF ΔARE/+ ileitis model are currently under way and may shed additional light on these findings.
One very important aspect of this study is the striking similarities in the decreased expression of the CB 1 R and CB 2 R in both murine and human chronic inflammation as compared with healthy controls, and in the increased expression of CB 1 R and CB 2 R in active murine ileitis and active, non-remission CD patients. This similarity lends credence to the translational applicability of our study in the search for novel therapeutic targets for IBD. However, we recognise that we see a decrease in CB 2 R expression in 20-week TNF ∆ARE/+ mice as well as in human IBD, despite previous evidence that there is continued increase in Tregs in intestinal inflammation in 20-week TNF ∆ARE/+ mice 32 and in IBD. 50, 51 The difference in expression of Tregs and CB 2 R is present because the CB 2 R is not exclusively expressed on Tregs, but rather is found on many immune cell types. 2, 11 In addition, whereas the differential expression of CB receptors in the colon has previously been classified, 27 the data collected in Figures  5A and C are novel in that, to the best of our knowledge, this is the first time the expression of the CB 2 R has been classified in the ileum. Understanding the role of the ECS in human IBD is paramount; genetic studies have associated a common CB 2 R functional variant, CB2-R63, with increased risk, worsening disease severity, and increased incidence of clinical relapse in paediatric IBD. 52 Our human data demonstrate a marked reduction in expression of the CB 2 R in diseased patients as compared with healthy controls, and this finding further justifies the importance of targeting the CB 2 R for resensitisation to promote restoration of gut homeostasis.
In summary, our study has demonstrated the significance of the endocannabinoid system in IBD. We propose that GP-1a acts upon the CB 2 R with inverse agonism in order sto allow receptor resensitization, promoting the endocannabinoid system to act at the CB 2 R on Tregs, thus attenuating inflammation in a mouse model of Crohn's disease. Given that CB 2 R stimulation attenuates murine ileitis, the anti-inflammatory influences of the endocannabinoid system hold promise as a new potential treatment modality for IBD. Our work elucidates a possible mechanism in the anti-inflammatory pathways of the ECS, which will contribute to the interpretation of data and greatly benefit the ongoing clinical trials in cannabinoids and IBD. 
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